The Program, which offers people the ability to participate in ketamine therapy at-home or in one of Field Trip’s locations, is designed to increase accessibility to psychedelic-assisted therapy for those suffering from mild to moderate depression, anxiety, and trauma and support it with a holistic approach to mental health and well-being.
Field Trip Health named one of the Top Five Best Psychedelic-Assisted Therapy Clinics in the world.
Both psychedelic drug use and talking about death are big stigmas in the western world—but one dying woman wants to change that.
Ketamine therapy pioneer Field Trip is partnering with telehealth company Nue Life to bring psychedelic treatments into the home.
Psychedelics have huge potential to treat a range of mental illnesses. Field Trip Health is one of dozens of companies to leap into a sector reminiscent of the early days of the cannabis craze.
Psychedelics seem poised to help a lot of people in a lot of pain.
Oregonians will soon have a front-row seat to what researchers and enthusiasts have dubbed the “psychedelic renaissance.”
Scientists are designing new psychedelic-inspired drugs that don’t yet exist, which might have effects no one can yet describe.
A doctor and a psychologist say Health Canada’s move to allow physicians to request restricted psychedelic drugs for patients as part of their psychotherapy is a positive step toward transforming mental-health care.
We announced that we will begin making applications for Canadians in need to access psilocybin-assisted and MDMA-assisted therapy through Health Canada’s Special Access Program (SAP). This announcement followed amendments to the SAP which have enabled physicians in Canada to make applications to Health Canada for access to “restricted drugs”, including psilocybin and MDMA.
The mind-altering drug has been shown to help people suffering from anxiety and depression. But how it helps, who it will serve, and who will profit are open questions.
"With ketamine clinics and psilocybin therapists and more places starting to come online, people are beginning to realize that the music part in all of this is actually really important."
We're doubling down on our mission to expand to new markets and bring the power of psychedelic-assisted therapy to the mainstream, as evidenced by our latest hire: Vicki Reed, a former CMO of Peloton, is joining the company as our Chief Growth Officer.
At least 12 ketamine clinics are operating in the Seattle area. The clinics, which have been sprouting across North America the past couple of years, use the drug to treat mental illness.
VR looks to cover the unmet need of assisting people unfamiliar with the use of psychedelics in clinical settings.
Quick Trip: Companies like Atai and Field Trip are developing second-generation psychedelic drugs that have modified duration times in an effort to condense therapy into a two-hour window.
It's a question as old as human consciousness: what happens after we die? While we may never have a full answer, there are plenty of first-hand accounts from individuals who have perhaps touched the boundaries between life and the great unknown via near death experiences (NDEs). In this episode of Spiraling, VICE producer Zeke Spector tries to conquer his own fear of death by attempting to recreate the conditions of an NDE in order to try and understand understand what death might teach us about life itself.
Psychedelic drug therapy is gaining popularity. Lauren had a traumatic delivery of her twins and carried the trauma with her, and she is about to try her first sessions of ketamine therapy. Vice president of the Field Trip Health Care Practice Matt Emer shares what the treatment entails. Watch as Lauren undergoes this treatment and shares how she feels just afterward.
"I've had depression for years now. I finally turned to a ketamine clinic for help."
After a 25 year military career, including two tours of Afghanistan, former master corporal Scott Atkinson struggled with post-traumatic stress disorder, depression, anxiety, and chronic pain. After finding some relief in medical cannabis, he became interested in psychedelic-assisted psychotherapy. Then, he went through six sessions of ketamine therapy at our Toronto clinic. “It’s changed my life,” he says. “It’s given me a way to go now. I’m not as angry all the time. The anxiety isn’t there all the time. It’s better with my family and with my kids. A year ago I was a completely different person.”
A W5 investigation into an unconventional treatment for severe depression and PTSD that involves the drug ketamine.
Jon Hopkins timed his upcoming album to the length of a ketamine high, while apps are using AI music to tailor drug experiences. Welcome to a techno-chemical new frontier.
Housewives in the Hills are doing it. Hipsters in Los Feliz, too. L.A. has became ground zero for a new hallucinogen boom, with ayahuas ca ceremonies now as common as barbecues. But is microdosing shrooms really the answer to what ails Angelenos?
Ronan Levy, our executive chairman, speaks with Toronto life about the impact and future of psychedelic therapies.
Janine Bajnauth speaks to Toronto Life about her experience with Ketamine-Assisted Psychotherapy at Field Trip Health.
Patrick Fletch speaks to Toronto Life about his experience with Ketamine-Assisted Psychotherapy at Field Trip Health.
Psychedelics may be one of the biggest recent breakthroughs in the mental health world, and Toronto’s Field Trip Health is determined to couple it with one of the oldest treatments in the book — psychotherapy.
A startup called Field Trip is opening clinics where they administer ketamine treatments. Other psychedelics, like MDMA and psilocybin, may follow.
Doctors are looking into psychedelics to possibly reduce anxiety and depression. NBC News’ Maya Eaglin reports on the new wave of mental health care.
Depression, often characterized by feelings of worthlessness, profound apathy, exhaustion and persistent sadness, affects 320 million people around the world. In a typical year in the U.S., roughly 16 million adults, or 7 percent, suffer from a depression-related illness such as major depression, bipolar disorder or dysthymia. Roughly one-third of those who seek treatment won't respond to verbal or conventional drug therapies. Magic-mushroom therapy is offering some hope for these hopeless cases.
Psilocybin and MDMA represent a first wave of therapies that help patients by changing the way they view reality.
Scientists treating depression and a range of other mental illnesses have been running controlled trials using MDMA and psychedelic drugs such as LSD and the results have been encouraging.
The growing legitimacy of psychedelics as therapies promises to transform how we view the extraordinary, writes Ed Prideaux of BBC.
The Globe and Mail surveys the current landscape in the psychedelic industry, and names some big key players in the Canadian space (us included!). Check out what executive chairman Ronan Levy has to say about the future of psychedelic drugs in modern medicine.
Resorts are starting to wake up to the appeal of mind expansion.
Scientists are working on a pharmaceutical device to help give people the best possible experiences on the likes of DMT and LSD.
Anna Mehler Paperny, author of the book Hello I Want To Die Please Fix Me, explores what it's like to take ketamine as a treatment option for treatment-resistant depression and discusses the landscape of current options in psychedelic treatment.
Field Trip Health stock on Thursday finished higher in its first day on the Nasdaq, making it the latest psychedelics-focused company hoping to use a big U.S. exchange to attract investors.
Field Trip Health, a Toronto-based psychedelic therapy clinic and drug development company, will list on the Nasdaq on Thursday through a direct listing. It is the fifth company focusing on psychedelic-assisted therapy to list on the exchange.
Keeping up with the surge of "cure-all" wellness fads is a job in and of itself. In our column Wellness Inspector, we do the work for you, closely examining these trends to see if they're worth your hard-earned pennies—or whether they're just hype.
After a half century spent waging war on drugs, Americans seem ready to sue for peace. The 2020 elections brought plenty of proof that voters have leapt ahead of politicians in recognizing both the failures of the drug war and the potential of certain illicit drugs as powerful tools for healing.
Today, a Google turn ups the number for the Psychedelic Peer Support Line, sponsored by Fireside Project, launched in April as a one-year pilot offering limited hours Thursdays through Mondays. The support line, which can be reached by texting or calling 62-FIRESIDE (623-473-7433), was envisioned by former lawyer Joshua White in the early months of the pandemic, when the possibility of widespread psychedelic healing was the one thing giving him hope.
A new study by researchers at Yale University has shown that a single dose of psilocybin given to mice prompted an immediate and long-lasting increase in connections between neurons. Psilocybin is a naturally occurring compound found in magic mushrooms and has been touted as a potential treatment for depression in recent years. However, the mechanics of exactly how psilocybin works in the brain and how long beneficial results might last is still unclear.
Psilocybin, a psychedelic compound that can be derived from over 200 species of mushroom, can remodel connections in the mouse brain. That is the conclusion of a new study that examined structural changes in the brain that might explain psilocybin’s enduring antidepressant effects.
Funded in part by Tim Ferriss, the Project on Psychedelics Law and Regulation will tackle the many unanswered legal questions facing psychedelic-assisted therapy.
This First Person article is the experience of Julian Uzielli, an associate producer with CBC Radio's Podcast Playlist. Facebook Twitter Pinterest Reddit LinkedIn Email Julian Uzielli says ketamine therapy has helped his chronic depression. Now, clinics are opening across Canada.
Field Trip Medical Director Dr. Michael Verbora & Executive Chairman Ronan Levy sit down with Nuvo Magazine to examine the current landscape of psychedelic healthcare, with an emphasis on our method of healing and the legalities of psilocybin.
The COVID-19 pandemic has amplified the spiraling mental health crisis in Canada. Here to talk about how psychedelic drug therapy can help is psychotherapist Dr. Mike Dow.
The former heavyweight champion says psychedelics would have helped him with his mental health during his career. Some scientists and companies agree.
Psychedelic therapy company Field Trip Health is looking to go public on the Nasdaq. Executive chair and co-founder Ronan Levy and former Senate Majority Leader Tom Daschle join ‘Squawk on the Street’ to make the case for investing in these therapies, the drugs involved and more.
One of the consequences of the pandemic is the dramatic growth of Telehealth and Telemedicine. But how can doctors and providers best care for their patients when they are not physically in front of them? What do doctors wish patients knew in order to make sure they are getting the best results even though they are not actually in the office? How can Telehealth approximate and even improve upon the healthcare that traditional doctors’ visits can provide?
A bill to legalize possession of psychedelics in California was approved by the California Senate on Tuesday. The legislation, sponsored by Sen. Scott Wiener (D), which previously cleared three committees, passed 21-16 on the floor.
Field Trip Health, Inc., a Toronto-based psychedelic-assisted therapy and drug development company, announced this month that former U.S. Senator-turned-lobbyist Tom Daschle will serve as a special advisor to the company. “Senator Daschle has participated in the development and debate of almost every major public policy issue of the last three decades and is a pre-eminent expert on health policy reform,” Joseph del Moral, co-founder and chief executive officer of Field Trip, said in a press release.
Lamar Odom Re/Born follows the former NBA superstar’s journey to break his addiction and anxiety with groundbreaking psychedelic medicines. Director Mike “Zappy” Zapolin, who is known as a psychedelic concierge, gives Lamar a psychedelic intervention using ketamine and ibogaine, along with a daily practice of meditation and breathing.
On the day it opened in early May, Field Trip Health’s therapeutic facility in Houston’s uptown neighborhood looked a little like a high-end strip-mall spa. Dressed in a floral shirt, Matt Emmer, the company’s director of operations and business development, showed me the clinic’s amenities. Field Trip, which launched in 2019 in Toronto and began opening clinics across North America in 2020, offers patients what is currently the only psychedelic drug with Food and Drug Administration approval for prescription: the anesthetic ketamine.
Ketamine assisted psychotherapy is now approved for use in Canada, so yes, it is safe. Ketamine is the only psychedelic approved in Canada for use in treatment-resistant depression, though it’s been around since the 50’s. It’s a super fast-working therapy that has shown significant improvement in patients in just 24 hours! It can also be co-prescribed with other antidepressants for a more profound effect.
One company pioneering the ketamine-assisted psychotherapy movement across North America is the psychedelic pioneers at Field Trip Health. They have opened several clinics across Canada and North America that, unlike other ketamine clinics, incorporate compassionate and comprehensive psychotherapy into the process. This guide explores their cutting-edge ketamine-assisted psychotherapy program for prospective clients and psychedelic enthusiasts alike.
Medical scientists have caught on to the fact that cannabinoids help fight unwanted inflammation that contributes to many diseases. But the next anti-inflammatory wonder drug could come from an even more unexpected source: psychedelics.
It’s no surprise people are turning to psychedelics for therapy. There’s a mental health crisis due to the pandemic, and therapy is expensive and not an option for many. Research is showing some incredible results with psychedelic-assisted therapy for an array of conditions and disorders. There's now an app for that.
Psychedelic drugs are helping people across Canada improve their mental health. Despite what your high school health teacher might have told you, a dose of ketamine, LSD or psilocybin (better known as magic mushrooms) – when administered in a controlled setting by a trained medical professional – can be highly effective in treating conditions like PTSD and depression.
“As a food, mushrooms have a lot of things going for them in terms of their nutritional value,” said Joshua Lambert, a co-director of the Center for Plant and Mushroom Foods for Health at the Penn State College for Agricultural Sciences. “But one of the things we’re looking into are the other compounds that mushrooms and other plants have that may have significant health benefits.”
Mike Dow, host of TLC's 'Freaky Eaters,' has joined Field Trip Health, which describes ketamine as a protocol "designed to help those suffering from treatment-resistant depression, generalized anxiety disorder and trauma."
A recent study found that microdosing psychedelic drugs had beneficial psychological effects – but so did a placebo. That might seem like a dose of cold water for this promising area of mental health treatment, but DLSPH Adjunct Prof. Dr. Dominique Morisano, Chief Psychologist at Field Trip Health, sees it differently.
The most exciting aspect of this trial is a sense that we are on the verge of a paradigm shift in mental healthcare linked to an improved understanding of the origins of depression, and how we can most effectively treat it. In my view, this shift will take us away from an outdated and myopic “drug-alone” perspective that has dominated psychiatry for several decades, and towards a multi-level “biopsychosocial” model.
It’s been almost 80 years since that fateful first acid trip but it looks as if Hofmann’s “problem child” might be getting past the bumpy road stage and growing up to face a promising future. Which makes this Bicycle Day one of LSD’s best birthdays ever. At least so far.
To manage her stress and fears, Andrea Bird -- who is suffering from terminal cancer -- uses psychedelics, which are seeing a sudden re-emergence in Canada as a possible treatment for mental health conditions such as anxiety and depression. The 60-year-old Canadian was diagnosed with breast cancer in 2012. Despite aggressive treatment, the disease returned five years later, spreading to her lungs, bones and brain.
2020 was a lot on our brains. Life can also be a lot on our brains. How do we cope with all of the trauma, anxiety, and baggage so that we’re not weighed down? A few options may have come to mind, but it’s unlikely that you’ve ever thought about anything like this! Introducing Field Trip Health, the groundbreaking company redefining mental well-being and consciousness through psychedelic-enhanced psychotherapy, recently opened its doors to Los Angelenos. We’re excited to share the news of Field Trip Health’s Los Angeles clinic opening, and highlight the revolutionary work FTH is doing to revolutionize mental health treatments using psychedelic-enhanced psycho-therapy.
“We are confident that this state-of-the-art facility and partnership with Field Trip will foster a wealth of innovation for the future of mental health research and therapies, even as we contribute to the regulatory framework that the Government of Jamaica (GOJ) is currently developing,” said Dale Webber, a professor, pro-vice-chancellor and principal at UWI.
Dr. Ben Medrano is psychiatrist and the medical director of Field Trip Health America. In an interview with The Dales Report last week, he shared some of the reasons behind his interest in the field of psychedelic-assisted psychotherapy, as well as some information about depression and the treatment available at Field Trip’s New York location.
For years, momentum has been building toward a brave new world in which psychedelic drugs, such as psilocybin, MDMA, and even LSD become accepted and approved mental health treatments. Although major strides have been made—MDMA is in final-stage clinical trials now—to bring these drugs out of the rave and into the pharmacy, none of them are likely to be available for at least another few years.
Field Trip Health announced Wednesday the closing of a CA$95 million ($76.5 USD million) offering. The raise is one of the largest in the sector’s history, and puts Field Trip’s cash on hand at roughly CA$113.7 million ($91.5 USD million).
Many people have a spiritual experience on psychedelics. How they make meaning of it could be influenced by the metaphysical beliefs of their therapists.
From approving religious exemptions to budgeting for medical research, advocates are hopeful that Biden and a Democratic Congress could mean progress for psilocybin and other therapeutic psychedelics
The world’s first legal research and cultivation facility dedicated to psilocybin-producing mushrooms and other plant-based psychedelics has opened in Mona, Jamaica. The facility, Field Trip Natural Products Limited Research and Development Laboratory for Psychedelic Fungi, is in partnership with Toronto-based Field Trip Health Ltd. and the University of West Indies (UWI).
A new partnership will see the world’s first legal research and cultivation facility dedicated exclusively to psilocybin-producing mushrooms and other plant-based psychedelics.
Psilocybin—the active compound in magic mushrooms—is one of a handful of psychedelic drugs that have shown real clinical promise in the treatment of anxiety, depression, and addiction.
The University of the West Indies (UWI), Mona, has entered into a partnership with Canadian company Field Trip Ventures Inc., in a new research facility dedicated to psychedelic fungi. Field Trip Natural Products (Ja) Limited Research and Development Laboratory, was formally launched on Tuesday, February 9, 2021, in an event held at the Faculty of Science and Technology at the UWI.
We’re in a shroom boom. One company, Compass Pathways, which plans to offer magic mushroom therapy, listed on the Nasdaq in November with a $1 billion valuation. New funds like Atai are raising hundreds of millions to invest in psychedelics. New companies are listing, new training programmes for therapists are launching, new states are preparing to legalize or decriminalize psychedelics.